ペニシリンGアシラーゼの世界市場

ペニシリンGアシラーゼの世界市場は2030年までに9億1,100万米ドルに達する見込み

2024年に7億2,750万米ドルと推定されるペニシリンGアシラーゼの世界市場は、2030年には9億1,100万米ドルに達し、分析期間2024-2030年のCAGRは3.8%で成長すると予測されます。本レポートで分析したセグメントの1つである大腸菌源は、CAGR 4.2%を記録し、分析期間終了時には5億6,880万米ドルに達すると予測されます。バチルス・メガテリウム（Bacillus Megaterium）源セグメントの成長率は、分析期間中CAGR 3.0%と推定されます。

米国市場は1億9,820万米ドルと推定される一方、中国はCAGR 7.1％で成長すると予測される

米国のペニシリンGアシラーゼ市場は、2024年には1億9,820万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを7.1%として、2030年までに1億8,450万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5%と3.0%と予測されています。欧州では、ドイツがCAGR 2.2%で成長すると予測されています。

世界のペニシリンGアシラーゼ市場- 主要動向と促進要因のまとめ

なぜペニシリンGアシラーゼは半合成抗生物質産業において重要な酵素なのか？

ペニシリンGアシラーゼ（PGA）は、ペニシリンアミダーゼとしても知られ、ペニシリンG（ベンジルペニシリン）を6-アミノペニシラン酸（6-APA）-半合成β-ラクタム抗生物質の合成の中核構成要素-に生体触媒的に変換する際に使用される工業的に重要な酵素です。この酵素プロセスは、危険な試薬と複雑な精製工程を伴う化学的加水分解に代わる、高収率で環境に優しい代替法を提供します。抗生物質に対する需要が世界的に増加し続けている中、PGAはアモキシシリン、アンピシリン、クロキサシリンなどのペニシリン誘導体のコスト効率が高く持続可能な生産において極めて重要な役割を果たしています。

酵素的経路は、基質特異性、より穏やかな操作条件、副生成物の減少など、いくつかの利点を提供します。抗生物質耐性が世界の公衆衛生の危機として顕在化する中、製薬メーカーには、より新しい製剤を開発し、レガシー抗生物質の安定生産を確保するという強いプレッシャーがかかり続けています。PGAベースのプロセスは、変換効率の向上、再利用能力、下流工程の統合のために最適化されつつあり、現代の抗生物質製造における酵素の重要性をさらに高めています。

プロセス工学と微生物株の革新は、どのように酵素収量と効率を高めているのか？

微生物バイオテクノロジーと発酵工学の進歩により、ペニシリンGアシラーゼの収量、活性、安定性が向上しています。大腸菌、バチルス・メガテリウム（Bacillus megaterium）、シュードモナス・プティダ（Pseudomonas putida）の遺伝子組み換え株は、PGAを過剰発現するように操作されており、多くの場合、下流での抽出を容易にするために分泌タグと融合されています。高細胞密度発酵とフェッドバッチ戦略は、工業的スケールで容積生産性を最適化し、酵素生産コストを削減しています。

ポリアクリルアミドゲルへの封入、シリカビーズへの共有結合、ポリマーマトリックスへのカプセル化などの酵素固定化技術は、複数の反応サイクルにわたる酵素の再利用を可能にしています。これらの技術は、熱安定性と操作寿命を向上させ、生産コストを大幅に削減します。連続フローリアクターやバイオ触媒リサイクルシステムによるプロセス強化も、生産性を向上させています。オンライン活性モニタリング、プロテオミクス、代謝モデリングなどの分析的進歩は、メーカーがPGA生産エコシステムを微調整し、効率と品質の一貫性を高めるのに役立っています。

ペニシリンGアシラーゼの需要を牽引している医薬品セグメントと地域市場は？

ペニシリンGアシラーゼの最大の消費者は、世界の抗生物質市場の大部分を占めるβ-ラクタム系抗生物質を専門とする製薬メーカーです。特に、細菌感染症、呼吸器疾患、尿路感染症、皮膚疾患の治療に使用される経口および注射用ペニシリン誘導体の製造において、需要は旺盛です。動物用抗生物質と市販の配合剤も酵素需要に大きく貢献しています。

アジア太平洋は、酵素生産と抗生物質の川下製剤の両分野で市場を独占しており、中国とインドは生産コストの低さと豊富な製薬能力を背景に、世界の製造拠点として機能しています。欧州は高度な生体触媒研究と高純度酵素アプリケーションのリーダーです。北米は、従来の抗生物質インフラと規制遵守要件を通じて安定した需要を示しています。アフリカ、ラテンアメリカ、東南アジアの新興国は、抗生物質へのアクセス向上と国家的なAMR（抗菌薬耐性）対策戦略により、消費の伸びを牽引しています。

ペニシリンGアシラーゼ市場の長期的成長と戦略開拓の原動力は？

ペニシリンGアシラーゼ市場の成長の原動力は、世界の抗生物質需要の拡大、持続可能なバイオ製造動向、酵素工学の進歩です。医薬品分野におけるグリーンケミストリーとクリーンルーム生産への注目の高まりは、従来の化学処理に代わる好ましい選択肢として酵素合成を強化しています。抗生物質の品質、トレーサビリティ、環境への影響に関する規制の監視が厳しくなるにつれて、酵素生産経路は組織的・商業的に支持されるようになっています。

戦略的には、酵素メーカーはAPIメーカー、CDMO（開発・製造受託機関）、学術コンソーシアムと協力し、オーダーメイドの生体触媒ソリューションを共同開発しています。独自の高収率PGA株のライセンシング、プラットフォームベースの酵素開発、リアルタイムのプロセスバリデーションが、競争上の重要な差別化要因として浮上しています。GMP認定酵素生産施設、AI支援プロセスモデリング、次世代バイオリアクターへの投資は、サプライチェーンをさらに近代化しています。微生物耐性と医薬品の持続可能性が世界の必須課題である時代において、PGAは次世代抗生物質生産システムの要となる酵素であり続けると思われます。

セグメント

供給源（大腸菌、バチルス・メガテリウム、その他の供給源）;用途（半合成ペニシリン製造用途、半合成セファロスポリン製造用途、その他の用途）;最終用途（製薬会社最終用途、学術・研究機関最終用途、その他の最終用途）

調査対象企業の例（全42件）

• ACS Dobfar S.p.A.
• Amicogen Inc.
• ASA Spezialenzyme GmbH
• Biosynth AG
• Carl Roth GmbH+Co. KG
• Crawford Wisdom International
• Creative Enzymes
• CSPC Zhongrun Pharmaceutical
• Fermenta Biotech Ltd.
• Hangzhou Junfeng Bioengineering Co., Ltd.
• Hebei Veyong Bio-Chemical Co., Ltd.
• Jiangsu Shennong Pharmaceutical
• Lonza Group AG
• Merck KGaA（Sigma-Aldrich）
• MuseChem Chemicals
• Parchem-Fine & Specialty Chemicals
• Shandong Lukang Pharmaceutical Co., Ltd.
• Sichuan Deebio Pharmaceutical Co., Ltd.
• Zhejiang Hisun Pharmaceutical Co., Ltd.
• Zhejiang Huahai Pharmaceutical Co., Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Penicillin G Acylase Market to Reach US$911.0 Million by 2030

The global market for Penicillin G Acylase estimated at US$727.5 Million in the year 2024, is expected to reach US$911.0 Million by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. E. coli Source, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$568.8 Million by the end of the analysis period. Growth in the Bacillus Megaterium Source segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$198.2 Million While China is Forecast to Grow at 7.1% CAGR

The Penicillin G Acylase market in the U.S. is estimated at US$198.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$184.5 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Penicillin G Acylase Market - Key Trends & Drivers Summarized

Why Is Penicillin G Acylase a Critical Enzyme in the Semi-Synthetic Antibiotics Industry?

Penicillin G acylase (PGA), also known as penicillin amidase, is an industrially significant enzyme used in the biocatalytic conversion of penicillin G (benzylpenicillin) into 6-aminopenicillanic acid (6-APA)-the core building block for the synthesis of semi-synthetic β-lactam antibiotics. This enzymatic process provides a high-yield, eco-friendly alternative to chemical hydrolysis, which involves hazardous reagents and complex purification steps. As demand for antibiotics continues to rise globally, PGA plays a pivotal role in the cost-effective and sustainable production of penicillin derivatives such as amoxicillin, ampicillin, and cloxacillin.

The enzymatic route offers several advantages including substrate specificity, milder operating conditions, and reduced by-product formation. With antibiotic resistance emerging as a global public health crisis, the pressure on pharmaceutical manufacturers to develop newer formulations and ensure consistent production of legacy antibiotics remains strong. PGA-based processes are being optimized for greater conversion efficiency, reuse capability, and downstream process integration-further reinforcing the enzyme’s centrality in modern antibiotic manufacturing.

How Are Process Engineering and Microbial Strain Innovations Enhancing Enzyme Yield and Efficiency?

Advancements in microbial biotechnology and fermentation engineering are improving the yield, activity, and stability of penicillin G acylase. Genetically modified strains of Escherichia coli, Bacillus megaterium, and Pseudomonas putida are being engineered to overexpress PGA, often fused with secretion tags for easier downstream extraction. High-cell density fermentation and fed-batch strategies are optimizing volumetric productivity and reducing enzyme production costs at industrial scale.

Enzyme immobilization techniques-such as entrapment in polyacrylamide gels, covalent binding to silica beads, or encapsulation in polymeric matrices-are enabling enzyme reuse over multiple reaction cycles. These technologies improve thermal stability and operational lifespan, significantly lowering production costs. Process intensification through continuous flow reactors and biocatalyst recycling systems is also improving productivity. Analytical advancements like online activity monitoring, proteomics, and metabolic modeling are helping manufacturers fine-tune the PGA production ecosystem for greater efficiency and quality consistency.

Which Pharmaceutical Segments and Regional Markets Are Driving Demand for Penicillin G Acylase?

The largest consumers of penicillin G acylase are pharmaceutical manufacturers specializing in β-lactam antibiotics, which account for a substantial portion of the global antibiotic market. Demand is particularly strong in the production of oral and injectable penicillin derivatives used in treating bacterial infections, respiratory illnesses, urinary tract infections, and skin diseases. Veterinary antibiotics and over-the-counter combinations also contribute significantly to enzyme demand.

Asia-Pacific dominates the market in both enzyme production and downstream antibiotic formulation, with China and India acting as global manufacturing hubs due to lower production costs and extensive pharmaceutical capacity. Europe is a leader in advanced biocatalysis research and high-purity enzyme applications. North America shows consistent demand through its legacy antibiotic infrastructure and regulatory compliance requirements. Emerging economies in Africa, Latin America, and Southeast Asia are driving consumption growth due to rising antibiotic access and national AMR (antimicrobial resistance) control strategies.

What Is Fueling Long-Term Growth and Strategic Development in the Penicillin G Acylase Market?

The growth in the penicillin G acylase market is driven by expanding global antibiotic demand, sustainable biomanufacturing trends, and advancements in enzyme engineering. The rising focus on green chemistry and cleanroom production in the pharmaceutical sector is reinforcing enzymatic synthesis as a preferred alternative to traditional chemical processing. As regulatory scrutiny tightens around antibiotic quality, traceability, and environmental impact, enzymatic production pathways are gaining institutional and commercial favor.

Strategically, enzyme producers are collaborating with API manufacturers, CDMOs (Contract Development and Manufacturing Organizations), and academic consortia to co-develop tailored biocatalysis solutions. Licensing of proprietary high-yield PGA strains, platform-based enzyme development, and real-time process validation are emerging as key competitive differentiators. Investments in GMP-certified enzyme production facilities, AI-assisted process modeling, and next-generation bio-reactors are further modernizing the supply chain. In an era where microbial resistance and pharmaceutical sustainability are global imperatives, PGA will remain a cornerstone enzyme of next-generation antibiotic production systems.

SCOPE OF STUDY:

The report analyzes the Penicillin G Acylase market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Source (E. coli, Bacillus Megaterium, Other Sources); Application (Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application, Other Applications); End-Use (Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• ACS Dobfar S.p.A.
• Amicogen Inc.
• ASA Spezialenzyme GmbH
• Biosynth AG
• Carl Roth GmbH + Co. KG
• Crawford Wisdom International
• Creative Enzymes
• CSPC Zhongrun Pharmaceutical
• Fermenta Biotech Ltd.
• Hangzhou Junfeng Bioengineering Co., Ltd.
• Hebei Veyong Bio-Chemical Co., Ltd.
• Jiangsu Shennong Pharmaceutical
• Lonza Group AG
• Merck KGaA (Sigma-Aldrich)
• MuseChem Chemicals
• Parchem - Fine & Specialty Chemicals
• Shandong Lukang Pharmaceutical Co., Ltd.
• Sichuan Deebio Pharmaceutical Co., Ltd.
• Zhejiang Hisun Pharmaceutical Co., Ltd.
• Zhejiang Huahai Pharmaceutical Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Penicillin G Acylase - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Demand for ?-Lactam Antibiotic Production Drives Use of Penicillin G Acylase in API Synthesis
  • Rising Focus on Enzymatic Green Chemistry Throws the Spotlight on Biocatalysts Like PGA
  • Expansion of Pharmaceutical Contract Manufacturing Accelerates Adoption of Efficient Enzymatic Processes
  • Integration of Immobilized Enzyme Systems Enhances Productivity and Reusability in Industrial Fermentation
  • Availability of Genetically Modified Strains Enhances Enzyme Yield and Activity Optimization
  • Stringent Environmental Regulations Encourage Shift From Chemical Synthesis to Biocatalytic Pathways
  • Increasing Use of Penicillin G Acylase in Semi-Synthetic Antibiotic Manufacturing Strengthens Global Demand
  • Advancements in Downstream Processing and Enzyme Purification Boost Industrial Scalability
  • Expansion of Biopharmaceutical R&D Programs Propels Custom Enzyme Engineering for Higher Selectivity
  • Rising Demand for Cost-Efficient and Sustainable API Production Drives Fermentation Route Adoption
  • Use of Recombinant Expression Systems Enhances Product Consistency in Large-Scale Enzyme Production
  • Availability of GRAS-Status Enzymes Supports Regulatory Compliance in Drug Manufacturing
  • Strategic Collaborations Between Biotech Firms and Enzyme Suppliers Fuel Innovation in Enzymatic Catalysis
  • Development of Thermostable and Solvent-Tolerant Variants Broadens Operating Window for Industrial PGA
  • Growing Interest in Enzyme Substitution for Hazardous Reagents Supports Green Pharmaceutical Processes
  • Increase in Outsourcing to Enzyme-Focused CDMOs Strengthens Business Case for Bulk Enzyme Supply
  • Challenges in Enzyme Recovery and Fouling Propel Demand for Membrane-Based and Flow Reactor Technologies
  • Rise in Asia-Based Antibiotic Production Facilities Expands Regional Demand for Penicillin G Acylase
  • Digital Bioprocess Monitoring Enhances Efficiency and Predictability in Enzyme-Driven Manufacturing
  • Growing Global Antibiotic Resistance Concerns Spur Innovation in Sustainable ?-Lactam Synthesis Routes
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Penicillin G Acylase Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Penicillin G Acylase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Penicillin G Acylase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Penicillin G Acylase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for E. coli by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for E. coli by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for E. coli by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Bacillus Megaterium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Bacillus Megaterium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Bacillus Megaterium by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Other Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Production of Semisynthetic Penicillin Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Production of Semisynthetic Penicillin Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Production of Semisynthetic Penicillin Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Production of Semisynthetic Cephalosporin Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Production of Semisynthetic Cephalosporin Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Production of Semisynthetic Cephalosporin Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Penicillin G Acylase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Penicillin G Acylase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Penicillin G Acylase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Penicillin G Acylase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Penicillin G Acylase by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Penicillin G Acylase by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Penicillin G Acylase by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Penicillin G Acylase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Penicillin G Acylase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Penicillin G Acylase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Penicillin G Acylase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Penicillin G Acylase by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Penicillin G Acylase by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Penicillin G Acylase by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Penicillin G Acylase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Penicillin G Acylase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Penicillin G Acylase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Penicillin G Acylase by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Penicillin G Acylase by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Penicillin G Acylase by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Penicillin G Acylase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Penicillin G Acylase by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Penicillin G Acylase by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Penicillin G Acylase by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Penicillin G Acylase Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Penicillin G Acylase by Source - E. coli, Bacillus Megaterium and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Penicillin G Acylase by Source - Percentage Breakdown of Value Sales for E. coli, Bacillus Megaterium and Other Sources for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Penicillin G Acylase by Application - Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Penicillin G Acylase by Application - Percentage Breakdown of Value Sales for Production of Semisynthetic Penicillin Application, Production of Semisynthetic Cephalosporin Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Penicillin G Acylase by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Penicillin G Acylase by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION